JP6173298B2 - 治療薬としての肝細胞増殖因子模倣体 - Google Patents
治療薬としての肝細胞増殖因子模倣体 Download PDFInfo
- Publication number
- JP6173298B2 JP6173298B2 JP2014503898A JP2014503898A JP6173298B2 JP 6173298 B2 JP6173298 B2 JP 6173298B2 JP 2014503898 A JP2014503898 A JP 2014503898A JP 2014503898 A JP2014503898 A JP 2014503898A JP 6173298 B2 JP6173298 B2 JP 6173298B2
- Authority
- JP
- Japan
- Prior art keywords
- hgf
- ile
- tyr
- dihexa
- met
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XDAPLUUFMJQLIZ-UHFFFAOYSA-N CCC(CCCNN)=O Chemical compound CCC(CCCNN)=O XDAPLUUFMJQLIZ-UHFFFAOYSA-N 0.000 description 1
- 0 CCCCIC(*)CN Chemical compound CCCCIC(*)CN 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161471124P | 2011-04-02 | 2011-04-02 | |
US201161471122P | 2011-04-02 | 2011-04-02 | |
US61/471,122 | 2011-04-02 | ||
US61/471,124 | 2011-04-02 | ||
PCT/US2012/031815 WO2012138599A2 (en) | 2011-04-02 | 2012-04-02 | Hepatocyte growth factor mimics as therapeutic agents |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014511858A JP2014511858A (ja) | 2014-05-19 |
JP2014511858A5 JP2014511858A5 (zh) | 2015-05-14 |
JP6173298B2 true JP6173298B2 (ja) | 2017-08-02 |
Family
ID=46969763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014503898A Active JP6173298B2 (ja) | 2011-04-02 | 2012-04-02 | 治療薬としての肝細胞増殖因子模倣体 |
Country Status (9)
Country | Link |
---|---|
US (3) | US9150613B2 (zh) |
EP (1) | EP2709650B1 (zh) |
JP (1) | JP6173298B2 (zh) |
CN (1) | CN103582490B (zh) |
AU (1) | AU2012240424B2 (zh) |
CA (1) | CA2832113C (zh) |
ES (1) | ES2622385T3 (zh) |
HK (1) | HK1196075A1 (zh) |
WO (1) | WO2012138599A2 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050048035A1 (en) | 2001-12-07 | 2005-03-03 | Fraser John K. | Methods of using regenerative cells in the treatment of stroke and related diseases and disorders |
US9597395B2 (en) | 2001-12-07 | 2017-03-21 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
US7771716B2 (en) | 2001-12-07 | 2010-08-10 | Cytori Therapeutics, Inc. | Methods of using regenerative cells in the treatment of musculoskeletal disorders |
US20050095228A1 (en) | 2001-12-07 | 2005-05-05 | Fraser John K. | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders |
WO2010021993A1 (en) | 2008-08-19 | 2010-02-25 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease |
US9051351B2 (en) * | 2011-04-02 | 2015-06-09 | Washington State University | Hepatocyte growth factor mimics as therapeutic agents |
WO2014021942A1 (en) * | 2012-08-01 | 2014-02-06 | University Of Southern California | Methods for limiting development of neurodegeneration |
EP3104708A4 (en) * | 2014-02-10 | 2017-08-09 | Cytori Therapeutics, Inc. | Regenerative cell therapy for central nervous system (cns) disorders and ptsd |
CN104788537B (zh) * | 2015-03-31 | 2018-03-13 | 中国科学院长春应用化学研究所 | 一种四肽化合物及其制备方法和应用 |
CN109563144B (zh) | 2016-06-01 | 2023-03-28 | 雅斯娜 | 化合物 |
GB201611123D0 (en) * | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
CN106699868B (zh) * | 2017-03-01 | 2019-11-15 | 牡丹江医学院 | 一种蛋白质及编码其的核苷酸序列 |
IT201800000535A1 (it) | 2018-01-03 | 2019-07-03 | Procedimenti per la cura del cancro. | |
CN110716925B (zh) * | 2019-09-05 | 2023-08-04 | 中电科大数据研究院有限公司 | 一种基于轨迹分析的跨境行为识别方法 |
US20230000943A1 (en) * | 2021-06-29 | 2023-01-05 | Synaptogenix, Inc. | Method of inducing synaptogenesis by administering angiotensin and analogues thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0662130B1 (en) | 1992-09-18 | 1997-11-26 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | A method of producing hepatocyte growth factor and a cell line |
US5854388A (en) * | 1993-06-24 | 1998-12-29 | Washington State University Research Foundation | Angiotensin IV peptides and receptor |
US6777388B1 (en) * | 1998-08-21 | 2004-08-17 | Clf Medical Technology Acceleration Program, Inc. | Leptin-related peptides |
US7192976B2 (en) * | 2002-12-21 | 2007-03-20 | Angion Biomedica Corporation | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
WO2008005531A2 (en) * | 2006-07-07 | 2008-01-10 | Washington State University Research Foundation | C-met receptor regulation by angiotensin iv (at4) receptor ligands |
WO2011019400A2 (en) * | 2009-08-12 | 2011-02-17 | Angion Biomedica Corp. | Enhancement of cellular transplantation using small molecule modulators hepatocyte growth factor (scatter factor) activity |
-
2012
- 2012-04-02 WO PCT/US2012/031815 patent/WO2012138599A2/en active Application Filing
- 2012-04-02 JP JP2014503898A patent/JP6173298B2/ja active Active
- 2012-04-02 AU AU2012240424A patent/AU2012240424B2/en active Active
- 2012-04-02 EP EP12768043.7A patent/EP2709650B1/en active Active
- 2012-04-02 ES ES12768043.7T patent/ES2622385T3/es active Active
- 2012-04-02 CN CN201280026925.2A patent/CN103582490B/zh active Active
- 2012-04-02 CA CA2832113A patent/CA2832113C/en active Active
- 2012-04-02 US US14/009,459 patent/US9150613B2/en active Active
-
2013
- 2013-02-15 US US13/768,497 patent/US8598118B2/en active Active
-
2014
- 2014-09-19 HK HK14109458.0A patent/HK1196075A1/zh unknown
-
2015
- 2015-08-07 US US14/821,184 patent/US20170049843A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HK1196075A1 (zh) | 2014-12-05 |
EP2709650A2 (en) | 2014-03-26 |
AU2012240424A1 (en) | 2013-10-17 |
US20130165392A1 (en) | 2013-06-27 |
CA2832113C (en) | 2020-07-21 |
WO2012138599A3 (en) | 2013-01-17 |
EP2709650B1 (en) | 2017-02-08 |
CA2832113A1 (en) | 2012-10-11 |
ES2622385T3 (es) | 2017-07-06 |
JP2014511858A (ja) | 2014-05-19 |
US8598118B2 (en) | 2013-12-03 |
WO2012138599A2 (en) | 2012-10-11 |
CN103582490A (zh) | 2014-02-12 |
CN103582490B (zh) | 2015-09-30 |
AU2012240424B2 (en) | 2017-10-26 |
US9150613B2 (en) | 2015-10-06 |
US20140088004A1 (en) | 2014-03-27 |
EP2709650A4 (en) | 2015-04-22 |
NZ616210A (en) | 2015-07-31 |
US20170049843A1 (en) | 2017-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6173298B2 (ja) | 治療薬としての肝細胞増殖因子模倣体 | |
ES2273849T3 (es) | Composiciones farmaceuticas que comprenden compuestos ciclicos peptidometicos con giro beta. | |
US20140094413A1 (en) | Hepatocyte growth factor (hgf) mimics as therapeutic agents | |
CN105431162B (zh) | 用于治疗血管生成依赖性和淋巴管生成依赖性疾病的生物模拟肽和生物可降解的递送平台 | |
JP6921755B2 (ja) | 脳腫瘍幹細胞の成長、遊走および浸潤性を低下させ脳腫瘍患者の生存率を改善する方法および組成物 | |
JP6640725B2 (ja) | spadinのレトロ−インベルソ類似体は増大された抗うつ作用を示す | |
PT2212349E (pt) | Análogos sintéticos de péptidos de regeneração neural | |
TW201412325A (zh) | 用於治療患有青光眼及其他退化性眼疾之人類視力喪失的間隔醫療 | |
US8138304B2 (en) | Neural regeneration peptides and formulations thereof | |
KR102532557B1 (ko) | Dsg2 유래 펩타이드 | |
US9051351B2 (en) | Hepatocyte growth factor mimics as therapeutic agents | |
ES2313777T3 (es) | Inhibidores de la neovascularizacion. | |
US7534436B2 (en) | Peptide fragments of the harp factor inhibiting angiogenesis | |
JP4778507B2 (ja) | 化学療法誘発末梢性ニューロパシーの治療のためのil6r/il6キメラ | |
JP2016169205A (ja) | 汗分泌促進剤及び該汗分泌促進剤を含有するドライスキンの予防薬又は治療薬 | |
NZ616210B2 (en) | Hepatocyte growth factor mimics as therapeutic agents | |
Class et al. | Patent application title: HEPATOCYTE GROWTH FACTOR (HGF) MIMICS AS THERAPEUTIC AGENTS Inventors: Joseph W. Harding (Pullman, WA, US) John W. Wright (Pullman, WA, US) Caroline C. Benoist (Nashville, TN, US) Leen H. Kawas (Pullman, WA, US) Gary A. Wayman (Pullman, WA, US) Assignees: WASHINGTON STATE UNIVERSITY | |
TWI740034B (zh) | 治療癌症之肽 | |
Kawas | Development of therapeutics targeting the hepatocyte growth factor (HGF)/MET system | |
Heskamp | Role of CXCL12 and CXCR4 in axonal regeneration of mature retinal ganglion cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150327 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150327 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20150409 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150409 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20150515 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160328 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160628 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160826 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170126 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170628 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170704 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6173298 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |